A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03616912 |
Recruitment Status :
Terminated
(Study terminated due to insufficient evidence to support a positive benefit: risk ratio. Safety findings were consistent with previously published OLUMIANT data)
First Posted : August 6, 2018
Last Update Posted : May 13, 2022
|
Sponsor:
Eli Lilly and Company
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Eli Lilly and Company
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Terminated |
---|---|
Actual Primary Completion Date : | November 1, 2021 |
Actual Study Completion Date : | March 9, 2022 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):